Literature DB >> 7370266

The interaction of daunorubicin and doxorubicin with DNA and chromatin.

F Zunino, A Di Marco, A Zaccara, R A Gambetta.   

Abstract

Isotherms that describe the binding of anthracycline antibiotics (including daunorubicin and doxorubicin (adriamycin)) to calf thymus DNA and chromatin have been obtained by means of fluorescence measurements. As expected for charged ligands, the association constants for the interaction of all drugs examined with DNA were found to be dependent on the ionic strength. However, in the case of the daunorubicin-DNA interaction, a marked decrease in the number of binding sites was also observed when the ionic strength was increased. It is suggested that the effect of salt concentration on the number of potential binding sites of daunorubicin molecules to DNA may be the result of some salt-induced alterations in the DNA conformation. This interpretation is also supported by binding data obtained with calf thymus chromatin; Whereas at low salt concentration the binding parameters for the doxorubicin-chromatin interaction are similar to those expected by neutralization of the phosphate groups by histones, modifications of the DNA structure in chromatin are invoked to account for the reduction and heterogeneity of daunorubicin binding sites. The side chain at C-9 could play an important role in determining the strength and specificity of the anthracycline-DNA interaction.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7370266     DOI: 10.1016/0005-2787(80)90073-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  21 in total

1.  Two design strategies for enhancement of multilayer-DNA-origami folding: underwinding for specific intercalator rescue and staple-break positioning.

Authors:  Yonggang Ke; Gaëtan Bellot; Niels V Voigt; Elena Fradkov; William M Shih
Journal:  Chem Sci       Date:  2012-08-01       Impact factor: 9.825

2.  Self-Assembled Aptamer-Nanomedicine for Targeted Chemotherapy and Gene Therapy.

Authors:  Nianxi Zhao; Zihua Zeng; Youli Zu
Journal:  Small       Date:  2017-12-04       Impact factor: 13.281

3.  Preferential inhibition of DNA polymerases alpha, delta, and epsilon from Novikoff hepatoma cells by inhibitors of cell proliferation.

Authors:  G Fox; O Popanda; L Edler; H W Thielmann
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

4.  Glycyrrhetinic acid-functionalized degradable micelles as liver-targeted drug carrier.

Authors:  Wei Huang; Wei Wang; Ping Wang; Chuang-Nian Zhang; Qin Tian; Yue Zhang; Xiu-Hua Wang; Rui-Tao Cha; Chun-Hong Wang; Zhi Yuan
Journal:  J Mater Sci Mater Med       Date:  2011-03-04       Impact factor: 3.896

5.  Muramyl dipeptide bound to poly-L-lysine substituted with mannose and gluconoyl residues as macrophage activators.

Authors:  D Derrien; P Midoux; C Petit; E Nègre; R Mayer; M Monsigny; A C Roche
Journal:  Glycoconj J       Date:  1989       Impact factor: 2.916

Review 6.  Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.

Authors:  V Ashutosh Rao
Journal:  Antioxid Redox Signal       Date:  2012-10-26       Impact factor: 8.401

7.  Effect of adriamycin on heart mitochondrial DNA.

Authors:  C N Ellis; M B Ellis; W S Blakemore
Journal:  Biochem J       Date:  1987-07-01       Impact factor: 3.857

8.  Differential susceptibility of immature rat testes to doxorubicin at critical stages of maturation. Biochemical and functional assessment.

Authors:  R Bechter; R Haebler; R A Ettlin; J K Haseman; R L Dixon
Journal:  Arch Toxicol       Date:  1987-08       Impact factor: 5.153

9.  Biochemical and biological activity of the anthracycline analog, 4-demethyl-6-O-methyl-doxorubicin.

Authors:  F Zunino; B Barbieri; O Bellini; A M Casazza; C Geroni; F Giuliani; A Ciana; G Manzini; F Quadrifoglio
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

10.  Synthesis, biological and biochemical properties of new anthracyclines modified in the aminosugar moiety.

Authors:  A Bargiotti; A M Casazza; G Cassinelli; A Di Marco; S Penco; G Pratesi; R Supino; A Zaccara; F Zunino; F Arcamone
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.